GTC
TXMD icon

Ghost Tree Capital’s TherapeuticsMD TXMD Stock Holding History

Ghost Tree Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,000
Closed -$2.93M – 69
2015
Q3 		$2.93M Buy
+10,000
New +$3.55M 1.32% 30

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ghost Tree Capital's TXMD Position: Q4 2016 in Review

Ghost Tree Capital sold out of TherapeuticsMD (TXMD) in Q4 2016, closing a stake of 5,000 shares — an estimated $1.7M sold.

Ghost Tree Capital first reported a position in TXMD in Q1 2014 and held it in 7 quarters. The position peaked at $3.63M in Q1 2015. 146 funds tracked by Wall St. Rank hold TXMD as of Q4 2016.

  • Ghost Tree Capital reported no remaining TherapeuticsMD position as of Q4 2016 after selling out during the quarter.
  • Ghost Tree Capital sold 5,000 TherapeuticsMD shares in Q4 2016, an estimated $1.7M.
  • Ghost Tree Capital first reported a position in TherapeuticsMD in Q1 2014 and held it in 7 quarters.
  • Ghost Tree Capital's TherapeuticsMD position peaked at $3.63M in Q1 2015.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2016.

Based on Ghost Tree Capital's 13F filing for Q4 2016, filed 14 Feb 2017.